Search Results for “immune” – Page 8 – media

Takeda and Noile-Immune Biotech Collaborate to Advance Next Generation CAR-T Cell Therapy Effective for Solid Tumors

A collaboration to develop next generation chimeric antigen receptor T cell therapy (CAR-T) (RELATED: Kite begins EU trial of CAR–T therapy) was announced by Takeda Pharmaceutical Company Limited (TSE: 4502) and Noile-Immune Biotech Inc..
- Source: Takeda
- 881
- September 6, 2017
antigen CAR–T Market Views receptor therapy
Over 5.7 billion! China’s dual antibody ADC goes global+1

On November 18th, VelaVigo Cayman Limited announced a global strategic partnership agreement with Avenzo Therapeutics, Inc. (Avenzo). According to the agreement, Orange Sail Pharmaceuticals will grant Avenzo the development, production, and commercialization of Nectin4/TROP2 bispecific antibody conjugates worldwide (excluding Greater China), while retaining relevant rights in Greater China. Both parties will jointly promote the development and clinical application of the project on a global scale. The project plans to submit an IND to the US Food and Drug Administration (FDA) and the National Medical Products Administration (NMPA) of China by 2025. According to the terms of the agreement, Orange Sail Pharmaceuticals will receive a down payment of up to $50 million and recent milestone payments. After achieving key milestones in development, regulatory approval, and sales, the company is expected to receive up to $750 million in follow-up milestone payments and tiered royalty payments based on sales in the Avenzo region. ...
- Source: drugdu
- 33
- November 21, 2024
Celltrion expands European market, acquires iQone Healthcare for 30 billion

On Friday, South Korean biosimilar giant Celltrion said it had completed the acquisition of iQone Healthcare Switzerland for approximately 30 billion won (about 155 million yuan) as part of its European expansion strategy. After the acquisition, iQone Healthcare Switzerland will become a wholly-owned subsidiary of Celltrion Healthcare Hungary Kft. The transaction will also provide Celltrion with the opportunity to obtain authorizations, further enhancing its pipeline of innovative therapies. In 2022, iQone’s annual revenue was 18.9 billion won (about 18.9 million US dollars), and sales increased by 57% to 29.6 billion won in 2023. Celltrion said the acquisition will further accelerate the expansion of its prescription drug business in Switzerland. According to IQVIA data, sales performance in the country remains strong, with the Ramsima series (IV and SC) accounting for 61% of the market share in the second quarter of this year. The company noted that its follow-up products are expected ...
- Source: drugdu
- 32
- November 20, 2024
Pumis announces equity acquisition agreement with BioNTech

According to the terms of the agreement, BioNTech will acquire 100% of Pumis’ issued share capital for a prepayment of $800 million (approximately RMB 5.781 billion) (subject to customary adjustment of the acquisition price), primarily in cash and a portion of American Depositary Shares (ADS). In addition, BioNTech will pay an additional milestone payment of up to $150 million (approximately RMB 1.084 billion) when Pumis meets the milestone conditions agreed upon by both parties. The transaction is expected to be completed in the first quarter of 2025, subject to customary delivery conditions and regulatory approvals. After the completion of this transaction, BioNTech will acquire full rights to the Pumis candidate drug pipeline and its bispecific antibody drug development platform, further expanding its business scope in China; Pumis Zhuhai will serve as the BioNTech China R&D center to conduct related R&D research; The Pumis Nantong production base, which meets international standards, ...
- Source: drugdu
- 44
- November 19, 2024
A “dark horse” has emerged in breast cancer treatment

The birth of blockbuster drugs in the field of breast cancer is not new. After all, there is fertile soil for the birth of big drugs here. The most core factor is the extremely large patient population. Breast cancer is one of the most common cancers and one of the leading causes of cancer-related deaths worldwide. In 2020, more than 2 million patients were diagnosed with breast cancer. In the United States, more than 290,000 patients are expected to be diagnosed in 2023. And the proportion of important subtypes is not low. For example, HR+ breast cancer is the most common breast cancer subtype, and more than 65% of breast cancer tumors are considered to be HR+/HER2 low expression or negative. Therefore, a strong demand for drugs has been created. The growth of HR+ breast cancer cells is usually driven by estrogen receptors (ER). Endocrine therapy for ER-driven diseases is ...
- Source: drugdu
- 36
- November 19, 2024
Four innovative pharmaceutical companies have completed a new round of financing! 3 from China

According to the Instant Drug Database, last week (November 4th to November 10th), at least four emerging companies dedicated to innovative drug research and development worldwide announced the completion of a new round of financing, including three Chinese companies. These emerging companies that have gained favor in the capital market are developing drug types such as gene therapy drugs, iPSC cell therapy drugs, peptide vaccines, and antibody conjugated drugs (ADCs) with dual payloads. Kanglin Biotechnology Financing round: Series A Financing amount: 150 million yuan On November 8th, Kanglin Biotechnology (Hangzhou) Co., Ltd. (referred to as “Kanglin Biotechnology”) announced the completion of a 150 million yuan Series A financing, jointly invested by Zhejiang Province’s “4+1” Biomedical and High end Device Industry Fund and old shareholder Zhejiang Miyin Investment Management Co., Ltd. Kanglin Biology was founded in 2015, focusing on the R&D and commercialization of innovative drugs for gene therapy, targeting diseases ...
- Source: drugdu
- 51
- November 13, 2024
1.82 billion, “China Resources” adds another member

On November 8, China Resources Boya Bio’s official website announced that “China Resources Boya Bio and Green Cross (China) meeting and work docking meeting were successfully held”. Two days ago (November 6), China Resources Boya Bio completed the acquisition of 100% equity of Green Cross (Hong Kong) and began to include it in the scope of consolidated financial statements. So far, “China Resources” has officially made another move in the blood products sector. In July this year, China Resources Boya Bio agreed to transfer 100% equity of Green Cross (Hong Kong) with its own funds of 1.82 billion yuan, thereby indirectly acquiring the domestic blood products entity Green Cross (China) (for details, please refer to the previous article “Spending 1.82 billion! China Resources Group takes action again”). As the blood products platform of China Resources’ big health sector, China Resources Boya Bio’s contribution to China Resources Pharmaceutical’s performance cannot be ...
- Source: drugdu
- 47
- November 13, 2024
Domestic lupus erythematosus drugs sold for 6 billion!

According to media statistics, in the first half of 2024 alone, at least 32 innovative pharmaceutical companies in China successfully completed BD projects, achieving cross-border expansion and involving transaction amounts exceeding 20 billion US dollars, with a significant increase in quantity compared to previous years. And this trend continues into the second half of the year, with domestic innovative pharmaceutical companies such as Ruige Pharmaceutical, Jiahe Biotechnology, Tongrun Biotechnology, and Anmai Biotechnology all having significant BD transactions. Recently, a domestic innovative pharmaceutical company that has only been established for eight years and currently has only a few pipelines under research sold one of its products, BD, for a sky high price. GlaxoSmithKline (GSK) has officially announced that it has reached an acquisition agreement with Chinese innovative pharmaceutical company Chimagin Biosciences for the three specific antibody CMG1A46. Accordingly, GSK will make a prepayment of $300 million to Enmu Biotechnology to acquire ...
- Source: drugdu
- 48
- November 12, 2024
The “trend” and “newness” behind Roche Pharmaceuticals’ layout of smart healthcare in China

Never underestimate the power of the tide. “AI+ empowerment” is becoming an important engine to promote the expansion of new quality productivity in various industries, and the medical and health system is no exception. For the medical and health system, improving productivity and efficiency while reducing the cost of patients and healthcare systems is an eternal topic. This also means that the greatest potential of AI+ healthcare lies not only in the application of one or two scenarios, but in assisting and optimizing medical services in all aspects, and completely rewriting the order of all links of “diagnosis and treatment”. At this year’s CIIE, through the display of Roche, the industry leader, we can see that this trend is already very obvious: AI is penetrating in multiple dimensions to meet the individualized diagnosis and treatment needs of patients and change the direction of the tide in multiple fields. Although many ...
- Source: drugdu
- 49
- November 12, 2024
The king of cancer is to be defeated

Pancreatic cancer is known as the “king of cancer” because of its high malignancy and lack of effective drug treatment. However, the research and development community has never stopped its efforts to conquer this type of cancer. Recently, Hengrui Medicine announced that the results of the Phase III study of irinotecan liposome (II) combined with advanced pancreatic cancer were published in the Nature sub-journal “Signal Transduction and Targeted Therapy”. The results showed that the irinotecan liposome combination regimen reduced the risk of death in pancreatic cancer patients by 37% compared with the control group. In the next era beyond chemotherapy, perhaps ADC drugs will become the main force in the fight against pancreatic cancer. For example, Innovent Biologics’ ADC targeting cluadin18.2 and Lepu Bio’s ADC targeting EGFR each have their own surprises, and both have shown breakthrough efficacy in the remission rate of pancreatic cancer. In addition, Kangfang has also ...
- Source: drugdu
- 46
- November 12, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.